SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Formerly About Advanced Micro Devices
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bonefish who wrote (1219420)4/11/2020 6:31:12 PM
From: SeachRE2 Recommendations

Recommended By
pocotrader
sylvester80

  Read Replies (1) of 1581708
 
A Shanghai HOCQ study as well as other French studies were not that impressive...these hospitalized CV19 patients are often very fragile(dehydration,low oxygen, failing kidneys and heart), unlike your average arthritis or lupus patients. There have been a few reports of serious heart toxicity here. OTOH, Gilead's Remdesevir came out with impressive numbers for patients with "severe disease" this AM, but the authors acknowledged the need for large RCTs still. RCT results will be available in a few weeks. So, things are moving...just because Trump says HOCQ is "a game changer" it doesn't have to be.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News